{"filings":[{"id":2216959,"accession_number":"0001193125-26-346859","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-08-12T20:10:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q2 2026 net loss $18.0M; cash $90.0M funds into Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.0M vs $21.0M in Q2 2025; R&D expense $13.8M vs $16.2M prior year.","Cash, equivalents and investments $90.0M as of Jun 30, 2026, expected to fund ops into Q4 2027.","ACR-368 Phase 2b prespecified interim analysis in serous EC on track for H2 2026; Phase 3 initiation planned H1 2027.","ACR-2316 entered randomized dose expansion at 120mg and 160mg oral QD in AP3-prioritized tumor types.","IND filing for CDK11 inhibitor candidate planned H1 2027; additional AP3 programs to start in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1113759,"accession_number":"0001193125-26-274410","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-06-17T21:28:03+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acrivon stockholders OK 3M share equity plan increase; elect Tomsicek, Baum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve increased by 3M shares to 8,606,723; annual 5% auto-increase through 2032 approved.","Michael Tomsicek and Charles Baum elected Class I directors until 2029 annual meeting.","PricewaterhouseCoopers ratified as independent auditor for fiscal year 2026.","Proposals passed with >65% of votes cast; quorum 73.21% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68205,"accession_number":"0001193125-26-221626","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-05-13T20:10:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.","Cash & equivalents $97.7M at March 31, 2026; plus $7.3M from equity financing, runway into Q3 2027.","ACR-368 Phase 2b registrational study: prespecified interim analysis of serous EC arms planned in H2 2026.","ACR-2316 Phase 1/2 shows tolerability and durable activity in AP3-prioritized lung cancers; expansion phase ongoing.","CDK11 inhibitor program (ACR-6840) IND submission targeted for H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108426,"accession_number":"0001193125-26-115139","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acrivon Therapeutics Q4/FY2025 net loss $19M/$77.9M; cash $118.6M; ACR-368 52% cORR in serous EC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $19.0M, FY $77.9M; cash and securities $118.6M expected to fund into Q2 2027.","ACR-368 Phase 2b showed 52% confirmed ORR in serous endometrial cancer; Arm 3 enrolling, Arm 4 to start H1 2026.","Completed exploratory Arm 2 (ACR-368 + ULDG) in biomarker-negative EC; objectives met with favorable tolerability.","ACR-2316 Phase 1 data shows tumor shrinkage in SCLC and squamous NSCLC; IND for ACR-6840 planned Q4 2026.","Launched wholly-owned CLIA lab for companion diagnostic development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108425,"accession_number":"0001193125-26-085516","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Acrivon terminates Akoya/Quanterix diagnostic deal; opens internal CLIA lab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually terminated OncoSignature Companion Diagnostic Agreement with Akoya (Quanterix) effective Feb 25, 2026.","No financial payments between the parties for termination; transition plan transfers testing procedures and materials to Acrivon.","Acrivon has completed and certified its own internal CLIA laboratory in Watertown, MA.","Acrivon now has full development and commercialization rights to its proprietary ACR-368 OncoSignature test.","Quanterix will continue to support ACR-368 clinical testing for Acrivon's ongoing Phase 2b study during the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108424,"accession_number":"0001193125-26-079500","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ACR-368 interim data from registrational-intent arms presented at ESGO for endometrial cancer serous subtype","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.","Data focused on endometrial cancer, particularly the serous sub-type.","KOL panel discussed potential of ACR-368 to address unmet need in this patient population.","Company-sponsored webcast with on-site and virtual participation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108423,"accession_number":"0001193125-26-007077","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon Therapeutics Provides Clinical Data Updates for ACR-368 and Initial ACR-2316 Data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On January 8, 2026, Acrivon hosted a webcast and conference call featuring ACR-368 clinical data and program updates.","Initial clinical data for ACR-2316 were presented during the webcast.","The presentation was posted on the company website at ir.acrivon.com under Investors & Media.","Exhibit 99.1 to the 8-K filing contains the January 8, 2026 Data Update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108422,"accession_number":"0001193125-26-007007","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Acrivon reports positive ACR-368 Phase 2b data in serous EC; ACR-2316 shows tumor shrinkage in Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.","ACR-2316 Phase 1: 33 patients dosed; tumor shrinkage in 9/20 evaluable; confirmed PR in EC, unconfirmed PRs in SCLC and sqNSCLC. Two weekly schedules set.","ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as development candidate; IND submission planned for Q4 2026.","Preliminary cash, cash equivalents and investments ~$119M as of Dec 31, 2025, expected to fund operations into Q2 2027.","Phase 3 confirmatory protocol for ACR-368 + anti-PD-1 submitted to FDA Nov 2025; global trial readiness expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124868,"accession_number":"0001193125-25-280172","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Therapeutics Q3 2025 net loss $18.2M, cash $134.4M to fund into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.2M for Q3 2025, improved from $22.4M in Q3 2024.","Cash, cash equivalents and investments of $134.4M as of Sep 30, 2025; funds operations into Q2 2027.","R&D expenses fell to $13.6M from $18.9M due to fewer milestones and trial prioritization.","Advancing ACR-368 Phase 2b trial for endometrial cancer; initial ACR-2316 Phase 1 data expected H2 2025.","Presented AP3 platform data at AACR-NCI-EORTC; new cell cycle program targets candidate nomination in 2025."],"consensus_eps_estimate":-0.6018,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141574,"accession_number":"0001193125-25-197250","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon reports new mouse-model data showing complete tumor regression and immune memory for ACR-368 and ACR-2316 combos","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.","Data supports rationale for front-line combination of ACR-368 and ACR-2316 with anti-PD(L)1 agents.","Pipeline update adds all-comer ACR-368 + ULDG ARM 3 of ongoing ACR-368-201 trial.","AP3 platform update highlights capability to generate actionable pathway insights for novel drug design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141573,"accession_number":"0001193125-25-179834","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q2 net loss $21.0M, cash $147.6M; advances ACR-368 and ACR-2316 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; R&D spend $16.2M.","Cash, equivalents and investments of $147.6M as of June 30, 2025; expected runway into Q2 2027.","Initiated Phase 2b third arm for ACR-368 with ultra low-dose gemcitabine in biomarker-unselected endometrial cancer.","ACR-2316 Phase 1 dose escalation shows initial clinical activity, including confirmed partial response in endometrial cancer.","Anticipated H2 2025 milestones: update on registrational ACR-368 trial and initial Phase 1 data for ACR-2316."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159419,"accession_number":"0000950170-25-086246","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acrivon stockholders elect three Class III directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 29,659,010 shares (94.59%) present at 2025 annual meeting on June 13.","Peter Blume-Jensen (26,612,623 for), Derek DiRocco (24,606,548), Santhosh Palani (26,246,868) elected as Class III directors.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 29,653,924 for, 3,673 against, 1,413 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159418,"accession_number":"0000950170-25-071385","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.","Cash, equivalents and securities $164.8M; runway into Q2 2027.","ACR-368 Phase 2b: 35% cORR, 80% DCR in OncoSignature+ patients; 50% cORR in relapsed subset.","ACR-2316 Phase 1: DL4 enrolling; ~25% tumor shrinkage at DL3 below projected RP2D.","Appointed Mansoor Raza Mirza as CMO; promoted Adam Levy to CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159417,"accession_number":"0000950170-25-051576","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.","Current CMO Jean-Marie Cuillerot departs on April 9, 2025.","Dr. Mirza will lead Phase 2b trial of ACR-368 for endometrial cancer and Phase 1 trial of ACR-2316.","He previously served as chief oncologist at Copenhagen University Hospital and medical director of NSGO CTU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177817,"accession_number":"0000950170-25-046163","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $184.6M as of Dec 31, 2024; runway extended into 2027.","ACR-368 in BM+ endometrial cancer: 35% cORR, 80% DCR; in relapsed patients cORR 50% with mDOR >10 months.","Phase 1 ACR-2316 cleared doses 1-2; dose 3 shows tumor shrinkage; target engagement confirmed.","Endometrial cancer prioritized; ovarian and bladder deprioritized due to competition/low BM+ rate.","R&D expenses $64.0M for FY24 vs $46.0M in FY23, driven by ACR-368 and ACR-2316 clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177816,"accession_number":"0000950170-25-044549","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.","ACR-368 BM+ endometrial cancer: 35% confirmed ORR, 80% DCR in 20 heavily pretreated patients (median 2 prior lines).","In BM+ patients refractory to last prior therapy (ORR 0%), ACR-368 achieved 33% ORR and 75% DCR.","Company deprioritized ovarian and bladder cancers; shifting resources to ACR-368 in endometrial cancer and ACR-2316.","ACR-2316 Phase 1: cleared DL2 without safety concerns; initial clinical activity observed in a patient at DL3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177815,"accession_number":"0000950170-25-039520","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.","Adam Levy, current SVP Corporate Affairs & Investor Relations, appointed CFO effective April 1, 2025.","Levy's annual base salary set at $490,000, bonus target 40%, plus 35,209 stock options vesting over 4 years.","Levy has over 25 years biopharma finance/IR experience, previously at Gilead, Turning Point Therapeutics, Zentalis.","Levy required to relocate to Boston area within 9 months; up to $50,000 relocation reimbursement with 24-month clawback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194516,"accession_number":"0000950170-24-125920","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.","Cash and securities $202.8M as of Sep 30, 2024; expected to fund into H2 2026.","ACR-368 Phase 2b endometrial cancer: confirmed ORR 62.5% in OncoSignature-positive patients (p=0.009).","ACR-2316 Phase 1 dose-escalation cohort fully enrolled; initial data expected H2 2025.","Company sees endometrial cancer as first potential approval opportunity for ACR-368."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194515,"accession_number":"0000950170-24-114213","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Acrivon doses first patient in Phase 1 trial of WEE1/PKMYT1 inhibitor ACR-2316","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed two quarters ahead of original timeline for ACR-2316 Phase 1 trial in solid tumors.","ACR-2316 advanced from initial lead to Phase 1 in 15 months using AP3 platform.","Initial clinical data from monotherapy dose optimization expected in 2H 2025.","Trial assesses safety, tolerability, MTD, RP2D, PK, and anti-tumor activity per FDA Project Optimus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210848,"accession_number":"0001193125-24-219180","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.","Statistically significant segregation of responders vs OncoSignature- arm (p=0.009); all responding patients still on therapy; mDoR not yet reached (~6 months).","Endometrial cancer anticipated as first potential accelerated approval opportunity for ACR-368.","FDA cleared IND for ACR-2316 (dual WEE1/PKMYT1 inhibitor); clinical sites activated; first-in-human dosing expected Q4 2024.","Cash of $220.4M (June 30, 2024) expected to fund operations into H2 2026; guidance reiterated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210847,"accession_number":"0000950170-24-095766","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.","Cash, equivalents and marketable securities $220.4M expected to fund into H2 2026.","ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive gynecological cancer patients.","ACR-2316 WEE1/PKMYT1 inhibitor Phase 1 on track to start 4Q 2024.","Raised $130M in oversubscribed private placement financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229254,"accession_number":"0000950170-24-075760","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acrivon Therapeutics stockholders elect three Class II directors and ratify PwC as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kristina Masson, Sharon Shacham, and Ivana Magovčević-Liebisch were elected as Class II directors with 24.6M, 23.3M, and 24.5M votes in favor, respectively.","PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal year 2024 with 27.4M for, 6,036 against, and 10,308 abstentions.","A quorum of 27.4M shares (88.81% of outstanding) was present or represented by proxy at the June 20, 2024 annual meeting.","Broker non-votes on director elections totaled approximately 2.7M shares, with none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229253,"accession_number":"0000950170-24-059097","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.","ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive patients (10) vs 0% in negative (16), p=0.0038.","Endometrial cancer identified as new AP3-predicted sensitive tumor type; median DoR not yet reached.","ACR-2316 IND expected Q3 2024; Phase 1 start Q4 2024.","Closed oversubscribed $130M private placement at premium; cash ~$240M pro forma into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229252,"accession_number":"0000950170-24-047560","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Acrivon reports 50% confirmed ORR with ACR-368 in OncoSignature-positive gynecological cancers; cash ~$234M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.","Median duration of response not yet reached; all responders remain on treatment.","ACR-2316 dual WEE1/PKMYT1 inhibitor IND filing accelerated to Q3 2024; clinical trial expected Q4 2024.","Preliminary cash $110M at March 31; pro forma $234M after private placement, funding into H2 2026.","Initial prospective validation of AP3 platform ability to predict ACR-368 responders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229251,"accession_number":"0000950170-24-042789","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.","Pre-funded warrants exercisable at $0.001/share, immediately exercisable, no expiration.","Investors include RA Capital, Perceptive Advisors, Paradigm BioCapital, Surveyor Capital, Sands Capital, Acorn Bioventures.","Proceeds to fund ACR-368 registrational trials, ACR-2316, cell cycle program, AP3 platform, AI/ML; cash runway into H2 2026.","Closing expected April 11, 2024; Jefferies acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247840,"accession_number":"0000950170-24-037627","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon reports Q4 2023 net loss of $19.3M; cash runway into Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $19.3M, full year $60.4M; R&D expenses $15.5M/$46.0M.","Cash, equivalents and marketable securities $127.5M at Dec 31, 2023; funds operations into Q4 2025.","ACR-368 Phase 2 trial enrolling; Phase 1b combo with gemcitabine completed; ACR-2316 IND studies advancing.","Two abstracts accepted for AACR 2024 on ACR-2316 and ACR-368 resistance mechanism.","Appointed Jean-Marie Cuillerot as CMO; added two new board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247839,"accession_number":"0001193125-24-056937","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acrivon appoints Santhosh Palani, Ph.D., CFA, to board of directors effective March 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Palani appointed board member effective March 4, 2024; receives 32,500 share option grant vesting over 3 years.","He brings experience as former investment partner at PFM Health Sciences and prior roles at NEA, Cowen, Pfizer, Takeda.","No transactions requiring disclosure under Item 404(a); standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247838,"accession_number":"0001193125-24-027629","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acrivon Therapeutics appoints Ivana Magovcevic-Liebisch, Ph.D., J.D., to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective February 8, 2024; she will receive 32,500 stock options vesting over 3 years.","Dr. Magovcevic-Liebisch is President and CEO of Vigil Neuroscience and brings 25+ years of industry experience.","She will enter into standard indemnification agreement and receive cash compensation per non-employee director policy.","No arrangements or transactions requiring disclosure under Item 404(a) exist with her selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247837,"accession_number":"0001193125-24-003885","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon updates corporate presentation at JPM; confirms cash runway into H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Participates in 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.","Updated corporate presentation includes product candidate development progress.","Confirms projected cash runway into the second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265272,"accession_number":"0001193125-23-291705","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Acrivon expands Akoya companion diagnostic deal to $17.3M for ACR-368 OncoSignature test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third Amendment with Akoya increases total milestone payments to $17.3M through FDA pre-market approval for multiple indications.","$3.8M in milestones already achieved and paid to date; cash runway unchanged from Nov 2023 10-Q.","Expanded scope of work covers development of ACR-368 companion diagnostic test across multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265271,"accession_number":"0001193125-23-274124","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acrivon Q3 net loss $14.5M; cash $142.1M; ACR-368 shows early clinical activity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.5M in Q3 2023 vs $9.2M in Q3 2022; R&D expenses $10.3M, G&A $5.9M.","Cash and marketable securities $142.1M as of Sept 30, 2023; expected to fund operations into H2 2025.","ACR-368: initial clinical activity observed in OncoSignature-positive patients across ovarian, endometrial, urothelial cancers; mature data H1 2024.","ACR-2316 dual WEE1/PKMYT1 inhibitor: IND submission planned Q4 2024; designed for superior single-agent activity via AP3 platform.","Two posters at AACR-NCI-EORTC conference validate ACR-368 OncoSignature assay with 47-58% ORR in tumor biopsies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282491,"accession_number":"0001193125-23-228639","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon announces dual WEE1/PKMYT1 inhibitor ACR-2316; plans IND by Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACR-2316 is a novel dual WEE1/PKMYT1 inhibitor designed using Acrivon’s AP3 precision proteomics platform.","Preclinical studies show single-digit nM IC50 potency and potent single-agent anti-tumor activity in vitro and in vivo.","IND-enabling studies underway; IND submission targeted for Q4 2024 to initiate monotherapy development.","Updated corporate presentation confirms cash and marketable securities as of June 30, 2023, with cash runway into 2025.","Company prioritizes ACR-2316 based on preclinical profile for OncoSignature-based patient selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282490,"accession_number":"0001193125-23-209745","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon posts Q2 2023 net loss of $13.9M; cash $151M funds ops into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.9M vs $5.8M in Q2 2022; R&D expenses $10.5M, up from $4.1M.","Cash, equivalents and marketable securities $151.0M as of June 30, 2023.","Registrational-intent Phase 2 trial of ACR-368 enrolling; initial data expected H2 2023.","FDA granted two Fast Track designations for ACR-368 in OncoSignature-positive ovarian and endometrial cancers.","Appointed Charles Baum to board and Adam Levy as SVP IR and corporate affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301716,"accession_number":"0000950170-23-029447","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acrivon Therapeutics stockholders elect two Class I directors and ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Tomsicek elected Class I director with 17,527,002 votes for and 226,168 withheld.","Charles Baum elected Class I director with 17,660,794 votes for and 91,113 withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2023: 17,879,658 for, 725 against.","Quorum of 17,880,383 shares (81.55% of outstanding) present at the 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301715,"accession_number":"0001193125-23-160789","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Acrivon Therapeutics amends EVP Kristina Masson's employment agreement with $382,200 base salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended employment agreement with Kristina M. Masson, EVP of Business Operations and board member, effective June 1, 2023.","Base salary set at $382,200; target annual bonus up to 40% of salary.","Separate Swedish employment agreement for role as President/CEO of Acrivon AB with base salary $163,800.","Severance: if terminated without cause or for good reason, 9 months base salary plus pro-rata bonus; enhanced terms after change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301714,"accession_number":"0001193125-23-138948","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Q1 net loss $12.8M vs $7.2M YoY; cash $159.5M; FDA Fast Track for ACR-368","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.8M for Q1 2023, widened from $7.2M in Q1 2022; R&D expense $9.8M (up from $6.1M).","Cash, equivalents and marketable securities $159.5M as of March 31, 2023; runway into Q4 2024.","FDA granted Fast Track designation for ACR-368 monotherapy in OncoSignature-positive platinum-resistant ovarian and endometrial cancer.","Phase 2 registrational trial of ACR-368 continues enrolling; initial clinical readouts expected H2 2023.","Advancing WEE1 and PKMYT1 inhibitor programs toward IND-enabling studies in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301713,"accession_number":"0001193125-23-129712","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon provides pipeline and AP3 update, reports cash runway into Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Hosted virtual investor event on May 1, 2023 with updated corporate presentation.","Disclosed cash and marketable securities as of March 31, 2023 (amount not specified in filing).","Confirmed cash runway extends into at least Q4 2024.","Presentation highlights progress on AP3 precision proteomics platform and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301712,"accession_number":"0001193125-23-128896","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Acrivon reports $159.5M cash as of March 31, 2023; runway into Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities totaled $159.5M as of March 31, 2023 (preliminary, unaudited).","Company confirms cash runway extends into at least the fourth quarter of 2024.","Preliminary estimate subject to change; actual results may differ materially.","Update provided in connection with virtual investor event on May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301711,"accession_number":"0001193125-23-114750","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acrivon updates pipeline and AP3 data; cash runway into Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities as of Dec 31, 2022 provide runway into at least Q4 2024.","OncoSignature enriched ORR to 47% (NCI trial) and 58% (Lilly trial) vs 0% in non-responders.","ACR-368 (CHK1/2) Phase 2 with registrational intent; new sensitive indications: endometrial and bladder cancer.","WEE1 and PKMYT1 inhibitors expected to enter IND-enabling studies in 2023.","Initial ACR-368 combination clinical readouts anticipated in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321480,"accession_number":"0001193125-23-081445","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acrivon Therapeutics reports FY 2022 net loss $31.2M, cash runway into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2022 was $31.2M vs $16.2M in 2021; Q4 net loss $8.9M vs $4.3M.","R&D expenses $23.9M in 2022, driven by ACR-368 Phase 2 trial and companion diagnostic agreement.","Cash, cash equivalents and marketable securities $169.6M as of Dec 31, 2022; expected to fund operations at least into Q4 2024.","FDA clearance received for IND of ACR-368 Phase 2 trial in platinum-resistant ovarian, endometrial, and urothelial cancers.","Initial Phase 2 data expected in second half of 2023; WEE1 and PKMYT1 programs advancing toward IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321479,"accession_number":"0001193125-23-068545","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acrivon reports $169.6M cash, runway into Q4 2024; ACR-368 OncoSignature enriches ORR to 47-58% in ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities $169.6M as of Dec 31, 2022 (preliminary, unaudited); projected runway into at least Q4 2024.","ACR-368 OncoSignature test enriched ORR to 47% (NCI) and 58% (Lilly) in blinded studies of platinum-resistant ovarian cancer biopsies.","Registrational-intent Phase 2 single-arm trials of ACR-368 monotherapy in OncoSignature-positive patients planned for ovarian, endometrial, bladder, and HPV SCC cancers.","Internal WEE1 and PKMYT1 inhibitors advancing to IND-enabling studies in 2023.","Past Phase 2 all-comer ORR for ACR-368 in platinum-resistant ovarian cancer was 12.1%; mDoR 5.6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321478,"accession_number":"0001193125-23-060173","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Acrivon Therapeutics sets 2023 annual meeting for June 22, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["First annual meeting of stockholders scheduled for June 22, 2023.","Rule 14a-8 stockholder proposals must be received by March 13, 2023.","Advance notice for director nominations and other proposals due by March 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339593,"accession_number":"0001193125-22-287727","cik":1781174,"company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["3.02","8.01","5.03","9.01"],"status":"ready","headline":"Acrivon Therapeutics completes IPO and concurrent $5M private placement with Chione Limited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO and concurrent $5M private placement with Chione Limited on Nov 17, 2022.","Issued 400,000 unregistered shares at $12.50/share to Chione under Section 4(a)(2) exemption.","Filed amended certificate of incorporation and bylaws effective upon IPO closing.","Shares in private placement are subject to lock-up and transfer restrictions; no public offering registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":70194837.39759037,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}